-
公开(公告)号:US11912644B2
公开(公告)日:2024-02-27
申请号:US17978734
申请日:2022-11-01
申请人: Celgene Corporation
发明人: John F. Traverse , Michael J. Zacuto , Weihong Zhang , Kirsten Faye Johnson , Maryll E. Geherty , Christopher Marton
IPC分类号: C07C231/18 , C07C231/12 , C07C237/06 , C07D209/46 , C07C275/70 , C07C237/12 , C07C273/18 , C07C275/24 , C07C67/313 , C07C231/02
CPC分类号: C07C231/18 , C07C67/313 , C07C231/02 , C07C231/12 , C07C237/06 , C07C237/12 , C07C273/1809 , C07C275/24 , C07C275/70 , C07D209/46 , C07C67/313 , C07C69/84 , C07C273/1809 , C07C275/06 , C07C231/12 , C07C237/06
摘要: Provided are processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof. Also provided are solid forms of various intermediates and products obtained from the processes.
-
公开(公告)号:US11484525B2
公开(公告)日:2022-11-01
申请号:US16921843
申请日:2020-07-06
申请人: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , FRIEDRICH-ALEXANDER-UNIVERSITÄT ERLANGEN-NÜRNBERG , THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY , THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
发明人: Brian K. Shoichet , Henry Lin , Peter Gmeiner , Aashish Manglik , Brian Kobilka , Bryan L. Roth , Daniela Gisela Dengler
IPC分类号: A61K31/381 , C07C275/26 , C07D401/12 , C07C275/24 , C07D207/452 , C07D233/16 , C07D498/18 , C07D333/16 , C07D249/04 , C07D409/12 , C07D471/04 , C07D333/20 , C07D295/125 , C07D333/58 , C07D495/04 , A61P25/36 , A61K31/165 , A61K31/17
摘要: Described herein, inter alia, are compositions and methods for modulating mu opioid receptor activity.
-
公开(公告)号:US20210387986A1
公开(公告)日:2021-12-16
申请号:US16979096
申请日:2019-03-13
发明人: Dean Sheppard , Aparna Sundaram , William F. DeGrado , Hyunil Jo
IPC分类号: C07D471/08 , C07D213/81 , C07C275/26 , C07C275/24 , C07D207/48 , C07D277/06
摘要: Disclosed herein, inter alia, are inhibitors of integrin alpha 2 beta 1 and methods of using the same.
-
公开(公告)号:US20210093603A1
公开(公告)日:2021-04-01
申请号:US16634935
申请日:2018-07-31
发明人: Fionn Hurley
IPC分类号: A61K31/27 , C07C333/04 , C07C307/02 , C07C275/24 , C07C233/11 , A61K31/255 , A61K31/17 , A61K31/165
摘要: The present invention relates to carbamoyl phenylalaninol analogs and methods of using the same to treat disorders.
-
公开(公告)号:US10780078B2
公开(公告)日:2020-09-22
申请号:US16104803
申请日:2018-08-17
申请人: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY , FRIEDRICH-ALEXANDER-UNIVERSITÄT ERLANGEN-NÜRNBERG
发明人: Brian K. Shoichet , Anat Levit , Aashish Manglik , Brian Kobilka , Peter Gmeiner , Harald Hübner , Daniela Gisela Dengler
IPC分类号: A61K31/381 , C07D333/24 , C07C275/24 , C07D333/20 , C07C225/20 , A61P25/36 , A61P25/22 , A61P25/04 , A61P25/24
摘要: Described herein, inter alia, are compositions and methods for modulating mu opioid receptor activity.
-
公开(公告)号:US20190276393A1
公开(公告)日:2019-09-12
申请号:US16156289
申请日:2018-10-10
IPC分类号: C07C275/16 , A61K39/385 , C07D213/38 , C07B59/00 , C07C275/30 , C07C275/24 , C07C311/19
摘要: Compounds of Formula (Ia) wherein R is a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl, a C1-C6 substituted or unsubstituted alkyl or —NR′R′, Q is C(O), O, NR′, S, S(O)2, C(O)2 (CH2)p Y is C(O), O, NR′, S, S(O)2, C(O)2 (CH2)p Z is H or C1-C4 alkyl, R′ is H, C(O), S(O)2, C(O)2, a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl or a C1-C6 substituted or unsubstituted alkyl, when substituted, aryl, heteroaryl and alkyl are substituted with halogen, C6-C12 heteroaryl, —NR′R′ or COOZ, which have diagnostic and therapetitic properties, such as the treatment and management of prostate cancer and other diseases related to NAALADase inhibition, Radiolabels can be incorporated into the structure through a variety of prosthetic groups attached at the X amino acid side chain via a carbon or hetero atom linkage.
-
公开(公告)号:US20190133123A1
公开(公告)日:2019-05-09
申请号:US16232392
申请日:2018-12-26
申请人: SHENZHEN UNIVERSITY
发明人: Shiguo CHEN , Lingjun Yuan
IPC分类号: A01N33/12 , A01N57/12 , A01N27/00 , A01N47/28 , A01N47/20 , A01N47/18 , A01N47/12 , A01N47/30 , A01N57/16 , D06M13/463 , D06M16/00 , D06M13/467 , D06M13/432 , D06M13/402 , D06M13/292 , D06M13/256 , C07F9/09 , C07D213/30 , C07C309/14 , C07C275/26 , C07C275/24 , C07C271/28 , C07C271/20 , C07D213/75 , C07C211/62 , D06M13/477
摘要: A reactive antibacterial compound is represented by the general formula (I): wherein R1 represents OCN-L-NHCOOR′, OCN-L-NHCONHR′, OCN-L-NHCOSR′, OCN-L-COOR′, or OCN-L-COONHR′. G1 represents OCN-M-NHCOOG′, OCN-M-NHCONHG′, OCN-M-NHCOSG′, OCN-M-COOG′, or OCN-M-COONHG′. L, M, R′ and G′ independently for each occurrence represent divalent alkyl and cycloalkyl having from 1 to 18 carbon atoms, optionally substituted by up to 18 heteroatoms. R4 and G4 independently for each occurrence represent a divalent alkyl and cycloalkyl having from 1 to 18 carbon atoms, optionally substituted by at most 18 heteroatoms. G2 and G3 independently for each occurrence represent —H, —F, —Cl, —Br, —I, —OCH3, —OCH2CH3, —OPr, —CN, —SCN, —NO, —NO2, a monovalent unsubstituted or substituted alkyl, cycloalkyl, or aryl having from 1 to 7 carbon atoms. Z and X independently for each occurrence represent —COO, —SO3, or —OPO2OR5. R5 represents a monovalent unsubstituted or substituted alkyl, cycloalkyl, or aryl having from 1 to 6 carbon atoms.
-
公开(公告)号:US10071056B2
公开(公告)日:2018-09-11
申请号:US15046817
申请日:2016-02-18
申请人: Pfizer Inc.
发明人: Stephen E. Zale , Mir Mukkaram Ali
IPC分类号: B82Y5/00 , A61K9/16 , A61K9/51 , A61K31/197 , A61K31/337 , C07C275/24 , C08G63/664 , C07C275/16 , C08G63/685 , C08G63/692 , A61K47/34 , A61K9/14 , A61K31/136 , A61K31/704 , A61K47/60 , A61K47/54 , A61K47/69
CPC分类号: A61K9/1647 , A61K9/146 , A61K9/5153 , A61K9/5192 , A61K31/136 , A61K31/197 , A61K31/337 , A61K31/704 , A61K47/34 , A61K47/542 , A61K47/60 , A61K47/6935 , A61K47/6937 , B82Y5/00 , C07C275/16 , C07C275/24 , C08G63/664 , C08G63/6852 , C08G63/6922 , Y10S977/904 , Y10S977/905 , Y10S977/906 , Y10S977/911 , Y10S977/915
摘要: The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries.
-
公开(公告)号:US20180072997A1
公开(公告)日:2018-03-15
申请号:US15565716
申请日:2016-04-22
发明人: John A. BENDER , Omar D. LOPEZ , Van N. NGUYEN , Zhong YANG , Alan Xiangdong WANG , Gan WANG , Nicholas A. MEANWELL , Brett R. BENO , Robert A. FRIDELL , Makonen BELEMA , Srinivasan THANGATHIRUPATHY
IPC分类号: C12N7/06 , C07C237/22 , C07C271/22 , C07C275/24 , C07C307/06 , C07C311/06 , C07C311/19 , C07D213/61 , C07D235/26 , C07D271/12 , C07D277/62 , C07D285/14 , C07D295/192 , C07D317/66 , C07K5/02
CPC分类号: C12N7/06 , C07C237/22 , C07C271/22 , C07C275/24 , C07C307/06 , C07C311/06 , C07C311/19 , C07C323/60 , C07C2601/08 , C07C2601/10 , C07C2601/14 , C07D213/61 , C07D235/26 , C07D271/12 , C07D277/62 , C07D285/14 , C07D295/192 , C07D317/66 , C07K5/022 , C12N2740/16063
摘要: Compounds of Formulas I-VI, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth. Formula I is exemplified below:
-
公开(公告)号:US20170369454A1
公开(公告)日:2017-12-28
申请号:US15635776
申请日:2017-06-28
申请人: Cornell University
IPC分类号: C07D249/06 , A61K9/00 , A61B6/03 , C07C275/24 , A61K51/04
CPC分类号: C07D249/06 , A61B6/032 , A61B6/037 , A61K9/0019 , A61K51/0497 , C07B2200/05 , C07C275/16 , C07C275/24
摘要: The present technology is directed to compounds, intermediates thereof, compositions thereof, medicaments thereof, and methods related to the imaging of mammalian tissue overexpressing PSMA. The compounds are of Formula I or a pharmaceutically acceptable salt thereof, wherein one of R1, R2, and R3 is and of Formula IV or a pharmaceutically acceptable salt thereof.
-
-
-
-
-
-
-
-
-